Tirzepatide-induced weight loss improves cardiometabolic markers in Chinese adults

Early weight loss associated with the use of tirzepatide may significantly improve cardiometabolic health, particularly in adults achieving a normal BMI by week 52, according to a China study. 

This post hoc analysis of the SURMOUNT-CN study involved 177 participants, of whom 62 were on tirzepatide 10 mg, 57 on tirzepatide 15 mg, and 58 on placebo. Those who achieved greater weight decrease (greater than or equal to the median percentage loss at 12 and 24 weeks) had more improved cardiometabolic markers. 

In addition, treatment with tirzepatide resulted in significant reductions in body weight, BMI, and waist circumference relative to placebo (p<0.05). 

Of the participants, 37 achieved a normal BMI (18.5–24 kg/m2, Chinese criteria) at week 52. Moreover, the metabolic syndrome dropped from 21.6 percent at baseline to 0 percent. 

“Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long-term metabolic health outcomes,” the investigators said. 

In this study, the investigators explored the relationship between tirzepatide and cardiometabolic risk factors in Chinese participants, categorized by Chinese-specific anthropometric cutoffs for BMI and waist circumference. They also assessed the association of early weight loss with cardiometabolic markers and metabolic syndrome.